Could cause temporary or reversible harm; serious harm is unlikely.
Failed Tablet/Capsule Specifications
| Brand name | BUPROPION HYDROCHLORIDE |
| Generic name | BUPROPION HYDROCHLORIDE |
| Active ingredient(s) | BUPROPION HYDROCHLORIDE |
| Distributed by / for | Graviti Pharmaceuticals Private Limited |
| NDC | 16571-863-03 |
| Full product label | Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, 30-count bottles, Rx Only, Mfd. by: Graviti Pharmaceuticals Private Limited, Sangareddy, Telangana, India, Dist. by: Rising Phar, NDC 16571-863-03. |
| Recalling firm | Graviti Pharmaceuticals Private Limited |
| Distribution | Product was distributed to 1 distributor and 16 wholesalers/pharmacy retailers nationwide. |
| Quantity | 46,512/30 count bottles |
| Recall initiated | 2025-09-15 |
| Report date | 2025-10-29 |
| Recall completed | — |
| Recall number | D-0037-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Hyderabad India |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗